Incidence, prevalence and antithrombotic management of atrial fibrillation in elderly Germans

Christoph Ohlmeier, Rafael Mikolajczyk, Wilhelm Haverkamp, Edeltraut Garbe

1 Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany
2 Helmholtz Centre for Infection Research, Braunschweig and Hannover Medical School, Hannover, Germany
3 Charité Universitätsmedizin Berlin, Berlin, Germany
4 University of Bremen, Bremen, Germany
5 Leibniz Institute for Prevention Research and Epidemiology - BIPS
6 Department of Clinical Epidemiology
7 Unit Epidemiology in Patient Populations
8 Achterstraße 30
9 D – 28359 Bremen
10 Christoph Ohlmeier, MPH
11 Leibniz Institute for Prevention Research and Epidemiology - BIPS
12 Department of Clinical Epidemiology
13 Unit Epidemiology in Patient Populations
14 Achterstraße 30
15 D – 28359 Bremen
16 Rafael Mikolajczyk, MD, MSc
17 Helmholtz Centre for Infection Research
18 Head of Research Group “Epidemiological and Statistical Methods”
19 Inhoffenstraße 7
20 D-38124 Braunschweig
21 Wilhelm Haverkamp, MD
22 Charité Universitätsmedizin Berlin
23 Deputy Head of Medical Department, Division of Cardiology
24 Augustenburger Platz 1
25 D – 13353 Berlin
26 Corresponding author
27 Edeltraut Garbe, MD, PhD
28 Leibniz Institute for Prevention Research and Epidemiology - BIPS
29 Head of Department of Clinical Epidemiology
30 Achterstraße 30
31 D – 28359 Bremen
1D – 28359 Bremen

Email: garbe@bips.uni-bremen.de

Phone: +49 421 218 56 862

Fax: +49 421 218 56 861
Abstract

Aims

Data on the epidemiology of atrial fibrillation (AF) and its antithrombotic management in elderly populations are scarce. The aims of this study were to estimate the incidence and prevalence of AF in the elderly in Germany and to describe antithrombotic management of AF cases.

Methods

Estimation of prevalence and incidence was based on data of three German statutory health insurances, which insured more than 800,000 people aged 65 years and older in the study period. The one year period prevalence of AF was estimated for each of the years 2004-2007. The incidence rate of AF in 2007 was assessed in patients with a preceding continuous three-year insurance period without diagnoses of AF. Antithrombotic management of AF was described among incident AF cases in 2008 and predictors for lack of prescriptions of oral anticoagulants were identified.

Results

Age-standardised period prevalence of AF among those 65 years or older was 7.7% in 2004, 9.4% in 2005, 9.8% in 2006 and 10.3% in 2007. The age-standardised incidence of AF was 2127.4/1,000 person-years in 2007. Prevalence and incidence increased with age and were higher in men than in women. In 2008, 58.2% of new AF cases received antithrombotic drugs. Treatment was less common among women and older people.

Conclusion

Incidence and prevalence of AF are relatively high in the elderly in Germany. A considerable fraction of new AF cases did not receive antithrombotic drugs in routine care.

Keywords

Atrial fibrillation, health insurance data, epidemiology, antithrombotic medication, Germany
Condensed abstract

Using a large health care database, we estimated incidence and prevalence of atrial fibrillation (27.4/100,000 person-years and 10.3%, respectively) in Germany among the ≥65 years old. Around 60% of patients with new atrial fibrillation diagnoses received antithrombotic drugs; this treatment was less common among women and at older age.
What's new?

- Information on the prevalence of atrial fibrillation in the elderly in Europe is scarce. Our study showed that the condition is common in the ≥65 years old in routine care in Germany (~10%).
- Based on consideration of also secondary hospital discharge diagnoses of atrial fibrillation, our study revealed higher incidence and prevalence estimates as previously reported, especially in the older age groups.
- Previous studies showed high proportions of patients with incident atrial fibrillation receiving antithrombotic treatment, but were restricted mostly to patients from specialised centres.
- In contrast, our study showed that a considerably higher fraction of patients with new atrial fibrillation diagnoses did not receive antithrombotic treatment in routine care, which applied to both patients with rhythm and rate control.
Introduction

Atrial fibrillation (AF) is the most common cardiac rhythm disorder and affects mainly older people (1, 2). The most serious complication of AF is stroke. AF is associated with an up to 5-4fold elevated risk for developing stroke, which is increasing with age (1). In people aged 80-589 years, approximately 25% of all strokes are due to AF (1). Strokes associated with AF are 6more likely to be severe and have a higher initial mortality than non-AF strokes (3, 4). In the 7context of demographic changes, the number of people suffering from AF will increase in the 8future. Modelling studies suggest a 2 to 3-fold increase in the number of AF cases by the year 92050 (1, 5, 6).

Antithrombotic management of AF was reported in several studies, but the results differed 11substantially. Some of these studies did not reflect routine care (7, 8), failed to include elderly 12AF patients (9) or were limited by low numbers of AF cases (9, 10). Moreover, the proportion 13of AF patients receiving antithrombotic drugs was possibly overestimated, since field studies 14based on voluntary participation of the treating physicians may have overrepresented those 15who already provide adequate antithrombotic treatment to their AF patients (7, 8, 10, 11).

For adequate planning of health care resources, knowledge about the epidemiology of AF and 17possible deficiencies in the care of AF patients is essential. However, reliable data on the 18epidemiology of AF in Europe and antithrombotic management of elderly AF patients in 19routine health care are scarce. Therefore, the aim of this study was to estimate incidence and 20prevalence of AF in the elderly in Germany and to assess antithrombotic management in these 21patients.

Methods

Data source

Source of data was the German Pharmacoepidemiological Research Database (GePaRD). This 25study was based on data from three statutory health insurances (SHI) including more than 8 27million insurants during the study period. The database was described elsewhere (12, 13). In 28brief, GePaRD contains demographic variables, information on hospital admissions, 29outpatient physician visits and data on outpatient prescriptions. The hospital data comprises 30information on admission diagnoses, main and secondary hospital discharge diagnoses, 31therapeutic and diagnostic procedures with their respective dates, admission and discharge 32dates and the reason for hospital discharge. Outpatient claims include information on 33outpatient treatments, procedures and diagnoses. Outpatient diagnoses, which are only related
1 to a quarter, can be distinguished into confirmed diagnoses, suspected diagnoses, diagnoses ruled out and status post diagnoses. Both, outpatient and inpatient diagnoses, are coded according to the German Modification of the International Classification of Diseases 10th Revision (ICD-10 GM) (14). Data on outpatient prescriptions of reimbursed drugs contains the date of prescription and dispensation, information on the prescribing physician, the pharmaceutical reference number and the amount of substance prescribed. Using the pharmaceutical reference number, prescriptions can be linked to the pharmaceutical reference database containing information on the anatomical-therapeutical-chemical (ATC) code, the defined daily dose (DDD), packaging size, strength, formulation, generic and trade name.

At the time of the study, data from two smaller SHIs were available for the years 2004-2007; one large SHI provided data for 2004-2008. Use of the data for research purposes needs to be approved by the SHIs contributing the data and by local or federal government authorities responsible according to data protection legislation. In accordance with § 75 of Volume 10 of the Social Insurance Code, informed consent of involved insurants was not required. Since the study was based on pseudonymised routine data delivered by the SHIs, a vote of the ethics committee was not required.

**Study design**

Estimation of the period prevalence of AF for each of the years 2004-2007 was based on cross-sectional analysis. To assess the incidence of AF in 2007, a retrospective cohort study was conducted. For 2008 data from only one company was available and this data was used to assess antithrombotic management of AF.

**Study population**

Included in the study population were people insured in one of the participating SHIs, if they had valid information on sex, year of birth and place of residence and were aged ≥65 years. For each of the different study populations, further inclusion criteria were applied.

Period prevalence of AF

For each of the study years, separate study populations were defined. Insurants had to be continuously insured during the study year or continuously insured until death in the respective year to be eligible for the study population.
Incidence of AF

For inclusion in the study population, insurants had to have an active insurance period in 2007, preceded by a continuous three-year insurance period without outpatient or hospital diagnoses indicating the presence of AF. Patients remained in the cohort until the end of the study period (31.12.2007), end of insurance period, death or first AF diagnosis, whichever came first.

Management of incident AF

The study population which was used to assess the management of incident AF included insurants who had been insured in the first three quarters of 2008, preceded by a continuous four-year insurance period without outpatient or hospital diagnoses indicating the presence of AF. Finally, insurants were included in the study population, if they had been diagnosed with AF in one of the first three quarters in 2008, so that data on prescriptions and procedures in the quarter of the AF diagnosis and the subsequent quarter could be used to describe the management of AF. Patients remained in the cohort until the end of the subsequent quarter, end of insurance period or death, whichever came first.

Definitions

Ascertainment of cases

Cases of AF were ascertained by using one of the following ICD-10 GM codes: I48.10 (paroxysmal atrial fibrillation), I48.11 (chronic atrial fibrillation), I48.19 (atrial fibrillation not further specified). To be identified as cases, insurants had to have at least one confirmed outpatient diagnosis, one main hospital discharge diagnosis or one secondary hospital discharge diagnosis with the above codes. Since an outpatient diagnosis can only be related to a calendar quarter, the date of the outpatient diagnosis of AF was defined as the middle of the quarter. In two sensitivity analyses we studied different combinations of the criteria for AF cases: (i) two confirmed outpatient diagnoses in different quarters or one hospital discharge diagnosis (main or secondary); or (ii) one confirmed outpatient diagnosis or one main hospital discharge diagnosis without consideration of secondary hospital discharge diagnoses.

Drug therapy

The proportion of incident AF patients receiving at least one antithrombotic drug and the proportion of incident AF patients receiving more than one antithrombotic drug was described
overall and stratified by treatment strategies of rhythm versus rate control. Both treatment strategies were defined by applying a modified definition originally proposed by Nieuwlaat et al. (7). A patient was assigned to rhythm control, if a class IA, IC or III antiarrhythmic drug (Vaughan Williams Classification (15)) had been prescribed or an electrical cardioversion had been conducted. Patients not included in the rhythm control group were classified into the rate control group, if they received prescriptions of digitalis, class II or class IV antiarrhythmic drugs. Cordichin (a combination drug of verapamil and quinidine) was classified as rhythm controlling agent.

Antithrombotic therapy was defined as at least one prescription of a vitamin K antagonist, antiplatelet drug, low molecular weight heparin, unfractionated heparin, heparinoid, direct thrombin inhibitor or other antithrombotic drug in the quarter of the AF diagnosis or the subsequent quarter.

Comorbidities
A range of comorbidities including risk factors and secondary diseases of AF was selected to describe the study population. These comorbidities were assessed using ICD-10 GM codes related to confirmed outpatient diagnoses, main hospital discharge diagnoses or secondary hospital discharge diagnoses during the respective study year (relevant codes are displayed in table 1 of the supplementary material).

Statistical analysis
Period prevalence of AF was calculated by dividing the cumulative number of AF cases in a given year by the mid-year population of the respective year. Corresponding confidence intervals (CIs) were calculated using the Wilson-Score method (16). CIs for age-standardised estimates were calculated according to the method based on the gamma distribution (17). Incidence rates of AF were calculated by dividing the number of incident AF cases by the accumulated person-time in the corresponding time period. CIs for incidence rates were calculated using the substitution method (18). Prevalence and incidence estimates were standardised using direct standardisation for the population distribution of ≥65 year-aged Germans in the respective year obtained from the German Federal Statistical Office. In two sensitivity analyses, the incidence and prevalence estimations were repeated applying both case definitions described above.
Using a logistic regression model, we determined predictors of lack of therapy with oral anticoagulants in incident AF patients. Independent variables contained in the full model included sex, age (5-year age categories), cardiac treatment strategy (rate control, rhythm control, neither), physician speciality of the AF diagnosing doctor (General Practitioner (GP), internist, other physician in private practice, physician in hospital), the CHA$_2$DS$_2$-VASc score (dichotomised into $\geq 2$ and $<2$) and selected comorbidities ascertained during a four-year period preceding the incident AF diagnosis (as shown in Table 1). Relevant factors were selected by backward elimination using the Wald test ($p<0.05$) to determine the final model. All statistical analyses were conducted using SAS 9.2 (SAS Institute Inc., Cary, NC).

Results

Prevalence of AF

AF cases were older and the proportion of men among AF cases was higher than in the total study population (Table 1). Assessed comorbidities were more frequent in AF cases than in the study population.

In 2007, the standardised prevalence of AF was 10.3% and was higher in men (11.4%) than in women (8.7%) (Table 2). The prevalence was 5.1% in the age-group 65-69 years and increased to 19.7% in the age-group 85-89 years (Figure 1). In patients aged $\geq 90$ years, the prevalence was slightly lower than in the preceding age group. Throughout the four study years, the prevalence of AF increased steadily. The increase in the prevalence of AF was seen in both sexes and all age-groups. The first sensitivity analysis in which two confirmed outpatient diagnoses were required for case ascertainment revealed slightly lower prevalence estimates. Here, the prevalence of AF in 2007 was 4.5% in patients aged 65-69 years and increased with advancing age to 18.1% in the age-group 85-89 years. Similar differences between the two estimation approaches were seen in both sexes (data not shown). The second sensitivity analysis which did not consider secondary hospital discharge diagnoses for case ascertainment resulted in lower prevalence estimates than the first sensitivity analysis, particularly in the oldest age groups. In this analysis, the AF prevalence was 4.6% in patients aged 65-69 years and 15.3% in those aged 85-89 years.

Incidence of AF

The overall standardised incidence of AF in 2007 was 27.4/1,000 py and was higher in men than in women (Table 3). The incidence of AF increased with advancing age from 13.2/1,000...
1py in patients aged 65-69 years to 67.7/1,000 py in the age-group ≥90 years and was higher in 
2men than in women across all age-groups. The incidence estimates from the first sensitivity 
3analysis which required two confirmed outpatient diagnoses for case ascertainment were 
4somewhat lower in both sexes. Here, the incidence rate of AF in 2007 was 7.7/1,000 py in the 
5age-group 65-69 and increased to 51.7/1,000 py in patients aged ≥90 years (data not shown). 
6The second sensitivity analysis which did not include secondary hospital discharge diagnoses 
7in the case ascertainment revealed considerably lower incidence rates of AF compared to the 
8main analysis. In this estimation approach, the incidence of AF was 10.1/1,000 py in the age 
9group 65-69 years and 31.3/1,000 py in patients aged ≥90 years.

10

11Antithrombotic drug management

12Of the 10,177 incident AF cases identified in 2008, 59.3% were newly diagnosed in hospital. 
13Of the 40.7% who were newly diagnosed in the outpatient sector, 52.5% received the first AF 
14diagnosis by an internist and 39.1% were diagnosed by a GP. Of the newly diagnosed AF 
15cases, 58.2% received antithrombotic drugs in the quarter of the AF diagnosis or in the 
16subsequent quarter (Figure 2). Antithrombotic drugs were more often prescribed to men 
17(61.8%) than to women (51.6%). The proportion of incident AF cases receiving 
18antithrombotic drug therapy declined with advancing age. In the age-group 65-69 years, 
1960.2% were supplied with antithrombotic medications, however, in the age-group ≥90 years 
20only 32.2% received an antithrombotic drug.

21In 59.1% of the incident AF cases, treatment was classified as rate control, whereas in 19.3% 
22of the cases - as rhythm control. The remaining 21.6% received no medications classified as 
23rhythm or rate control in the quarter of the AF diagnosis or in the following quarter. AF 
24patients treated with rhythm control received more often antithrombotic agents (75.2%) than 
25patients treated with rate control (61.3%) (Table 4). In particular, vitamin K antagonists and 
26low-molecular-weight heparin were more rarely prescribed in patients with rate control than 
27in those with rhythm control. Patients, whose rhythm disorder remained untreated, were 
28considerably less often treated with antithrombotics (34.7%). Heparinoids and direct thrombin 
29inhibitors were not prescribed in our study population of AF patients. With regard to the 
30dichotomised CHA2DS2-VASc score, only slight differences in the proportion of patients 
31without oral anticoagulation treatment were observed between patients with a CHA2DS2-
32VASc score of 0-1 compared to those with a CHA2DS2-VASc score of ≥2 (69.2% versus 
3361.7%). The multivariate analysis showed that increasing age, female sex, rate control or no
1 therapy strategy (neither rhythm control nor rate control) compared to rhythm control
2 myocardial infarction, valvular heart disease, diabetes mellitus, chronic renal failure and a
3 CHA\textsubscript{2}-DS\textsubscript{2}-VASc score of 0-1 were associated with a significantly increased risk of not
4 receiving oral anticoagulants after incident AF diagnosis, whereby especially subjects aged 90
5 years or older were less likely to receive oral anticoagulants (Table 5).

7 Discussion
8 Using data from a large German health insurance database we assessed prevalence, incidence
9 and antithrombotic drug treatment of AF in Germany. The incidence and prevalence increased
10 with advancing age and were higher among men than women. More than 40\% of incident AF
11 cases received no antithrombotic drug treatment in 2008.
12 The prevalence of AF estimated in our study is somewhat higher than the estimates derived
13 from the considerably older, population-based Rotterdam Study which was conducted
14 between 1990 and 1999 (19). In this study, the prevalence of AF was 4.0\% in the age-group
15 65-69 years (5.1\% in our study) and similarly showed a marked increase with age. In subjects
16 aged 80-84 years, the prevalence of AF was 13.5\% in the Rotterdam Study compared to
17 16.5\% in our study. In contrast, we found a lower AF prevalence in our study than the recently
18 published population-based Gutenberg Health Study (GHS) in Rhineland Palatinate (9). This
19 is not surprising since in the GHS active screening for AF with a 12-lead electrocardiogram
20 was conducted in addition to obtaining the medical history of the patient in an anamnestic
21 interview. In the GHS, the prevalence of AF was provided in 10-year age bands up to the age
22 of 74 years and was 10.6\% in men and 4.9\% in women aged 65-74 years, whereas it was
23 23.7\% and 4.2\% in this age group in our study, respectively.
24 Our prevalence estimates of AF are somewhat higher than those of another recently published
25 German study which was also based on claims data (20). This study by Wilke et al. (20)
26 estimated the prevalence of AF at 4.8\% in patients aged 65-69 years and at 15.1\% in the age
27 group 85-89 years (5.1\% and 19.7\% in our study, respectively) using a different algorithm for
28 case ascertainment. This algorithm required one main hospital discharge diagnosis or two
29 outpatient diagnoses in two different quarters and was used in analogy to the algorithms
30 applied in the German morbidity-based risk structure equalisation scheme (21), where two
31 outpatient diagnoses are required in order to improve security of the diagnosis. Since AF is an
32 intermittent disease, which is characterised by short and rare episodes particularly at the
33 beginning of the disease, a first AF diagnosis has not necessarily to be followed by a second
AF diagnosis in the same year (22). Therefore we applied an algorithm based on a single diagnosis only. Requiring a second outpatient diagnosis of AF in another quarter in our first sensitivity analysis resulted in a similar prevalence for those aged 65-69 years as in the study by Wilke et al. (20), but still yielded a higher prevalence in the older age groups in our study. As our second sensitivity analysis which did not consider secondary hospital discharge diagnoses for case ascertainment revealed prevalences similar to those of Wilke et al., the difference between our and the Wilke study at higher age is likely due to the fact that the algorithm for case ascertainment by Wilke et al. did not consider secondary hospital discharge diagnoses of AF. From the hospital diagnoses, Wilke et al. only included patients with a main hospital discharge diagnosis, which in the German coding system states the disease giving rise to the hospitalisation. Since up to 30% of AF patients have asymptomatic AF (23), it might not be infrequent that AF is detected first during the routine examinations in the context of a hospital stay which was due to another disease.

The incidence rates of AF from our study are most comparable with the results of the Cardiovascular Health Study (24). In this study, 18.0% of the incident AF cases were solely identified based on diagnoses reported by the patients which may have led to over- or underestimation of incidence, since patients could have forgotten about the arrhythmia or could have confused AF with another arrhythmia (24). The Rotterdam study (19), the US ARIC-Study (25) and another US study reported by Miyasaka et al. (5) reported lower incidence rates of AF in comparison to our study. In the ARIC study, only inpatient diagnoses were used to identify AF cases which presumably led to a considerable underestimation of the incidence rate, since AF does not necessarily require inpatient treatment. Only 67% of AF patients in our study were identified by inpatient diagnoses so that 33% of the patients would have been missed had the outpatient diagnoses not been considered. In comparison to the study by Wilke et al. (20), the incidence estimates in our study were also higher with the difference being most pronounced in the oldest age groups. These differences likely result from the different case finding algorithms used in both studies, as already discussed above. In particular, the non-consideration of secondary hospital discharge diagnoses may have led to the lower incidence estimates in the study by Wilke et al. since our second sensitivity analysis, in which only confirmed outpatient diagnoses and main hospital discharge diagnoses were considered revealed comparable estimates to the results provided by Wilke et al.

Comparing our incidence and prevalence estimates with those from other studies, it has to be taken into account that most other studies were conducted in the late 1980’s or 1990’s (1, 19,
and this has several implications. Improved survival of patients with cardiac diseases has led to an increase in elderly patients who are at high risk of AF. Furthermore, a growing awareness of AF among physicians may have resulted in a smaller proportion of undetected AF cases. Therefore the higher estimates in our study were to be expected compared to those from these earlier studies. Our similar prevalence estimates to those of the considerably older Rotterdam study (19) may be explained by the active screening approach for AF in the Rotterdam study which would be expected to outweigh the lower prevalence during the time period of its study conduct (26).

Our estimates regarding the proportion of incident AF cases receiving antithrombotic therapy in general as well as defined antithrombotic agents compare well with the results of the recently published GHS study (9), but are considerably lower than the estimates reported by the Euro Heart Survey (7) or those of the Registry of the German Competence Network on Atrial Fibrillation (AFNET) (8). All AF patients participating in the Euro Heart Survey and 1467% of AF patients participating in the AFNET were treated in specialized university hospitals or cardiologist centres (7, 8) who have been shown to provide adequate antithrombotic treatment more frequently (27). In our study, a more balanced distribution regarding the sector of the diagnosis and the physician speciality of the AF diagnosing doctor was seen. Both in the Euro Heart Survey and the AFNET, the participating centres are presumably not representative for anticoagulant management of AF patients in routine care, but are likely to include a selected sample of physicians who due to their scientific interest in the study question are more likely to provide adequate antithrombotic therapy in accordance with current guidelines. It is an advantage of our study that it includes all physicians who care for AF patients thereby avoiding a selected sample of physicians. A further explanation for the lower proportion of AF patients with antithrombotic therapy in our study may be that acetylsalicylic acid (ASA) in the therapy of AF is not reimbursed by the SHIs in Germany, so that the data source of our study did not contain such claims. Wilke et al. (28) also evaluated the antithrombotic management of patients with AF and also showed an underuse of treatment with antithrombotic drugs, but since this study focussed on the antithrombotic therapy of prevalent AF cases and used other methods to evaluate the antithrombotic treatment, we did not compare our results to this study.

Limitations
At the time of the analysis, health insurance data were only available to us until the end of 2008. It was therefore not possible to study which impact the newer oral anticoagulants might have on the antithrombotic management of AF patients. Further, health insurance data have only been available to us since 2004. Calculation of the CHA$_2$DS$_2$-VASc score was limited by this fact, since prior diagnoses of stroke or ischaemic attack were not available to us before 2004. In some cases, patients could have had diagnoses of AF prior to 2004 and would thus be misclassified as incident cases in 2007, although they were prevalent cases. However, such misclassification is probably of low magnitude, since it is unlikely that an AF patient will not see his physician for three years and will not obtain the AF diagnosis in his records.

A validation of the AF diagnosis in our data by chart review could not be carried out for reasons of protection of personal data. However, we assume a valid coding of AF diagnoses in SHI data, since our results regarding the prevalence of AF were similar to the German GHS-study or showed expected differences (9).

Due to lack of specific codes it could not be clearly distinguished between rhythm and rate controlling catheter ablations. Therefore catheter ablations could not be taken into account when defining rhythm and rate control, which could have led to an underestimation of both treatment strategies. However, this potential underestimation is suspected to be rather small, since catheter ablations are rarely performed in incident AF cases.

Since many contraindications for the use of antithrombotic agents in patients with AF cannot adequately be operationalized in claims data, we did not exclude patients with contraindications when evaluating the antithrombotic treatment in incident AF patients, which could have led to an overestimation of undertreatment. However, since these contraindications are rare disorders, not accounting for them will likely not change the results of undertreatment with antithrombotics to a relevant extent.

The categorization of the physician speciality in claims data is rather unspecific, as for example cardiologists cannot be distinguished from gastroenterologists, since both are coded as internists in our data. This presumably led to the fact that the physician speciality had no influence on receiving oral anticoagulants in the multivariate logistic regression model, although this is a known association in other studies (27).

Strengths

The major strength of this study is the large study sample, which allowed a precise estimation of incidence, prevalence and antithrombotic treatment even in the highest age-categories.
Since this study is based on administrative data, recall bias or selection bias (e.g. due to voluntary participation of patients or physicians) could be avoided. We further did not restrict our analyses on the antithrombotic treatment of incident AF to selected physician specialities, so that our results are more likely to reflect routine care. In addition, it could be shown that the age- and sex-distribution as well as drug use of patients included in GePaRD is similar to that of Germany, leading to a high external validity of the results (12, 29).

In conclusion, our study showed that the incidence and prevalence of AF in elderly people in Germany is rather high. Compared with incidence and prevalence estimates of older studies, an increase of the incidence and prevalence can be assumed. Our analysis revealed a considerable fraction of AF patients who were not treated with antithrombotic drugs, whereby especially old-aged people and women had a high risk of not receiving antithrombotic treatment.

In the context of an aging society and therefore increasing numbers of multi-morbid AF cases at a high risk of stroke, providing adequate antithrombotic therapy is an important task for the physicians and interventions are necessary to improve the current situation.

Acknowledgements

The authors are grateful to all statutory health insurances that provided data for this study, namely the Allgemeine Ortskrankenkasse (AOK) Bremen/Bremerhaven, the Techniker Krankenkasse (TK), and the hkk.

Conflict of interest

Christoph Ohlmeier: None declared
Rafael Mikolajczyk: Rafael Mikolajczyk received research funding from Sanofi Pasteur MSD (SPMSD) and Bayer-Pharma
Wilhelm Haverkamp: Wilhelm Haverkamp has received honoraria and research funding from several pharmaceutical companies. However, the present work is unrelated to any grant and relationship.
Edeltraut Garbe: Edeltraut Garbe is running a department that occasionally performs studies for pharmaceutical industries with the full freedom to publish. The companies include Mundipharma, Bayer, Stada, Sanofi-Aventis, Sanofi-Pasteur, Novartis, Celgene, and GSK.
She has been consultant to Bayer-Schering, Nycomed, Teva, GSK, Schwabe and Novartis in the past. The present work is unrelated to the above grants and relationships.


Figure legends

Figure 1: Age- and sex-stratified prevalence of atrial fibrillation in 2007. Error bars represent 95% confidence intervals.

Figure 2: Age- and sex-stratified proportions of incident cases with atrial fibrillation receiving antithrombotic therapy. Error bars represent 95% confidence intervals.
## Text tables

### Table 1: Characteristics of the study population and patients with atrial fibrillation in 2007

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Study population</th>
<th>AF-cases</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td><strong>Age groups</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-69</td>
<td>383,966</td>
<td>47.3</td>
</tr>
<tr>
<td>70-74</td>
<td>211,713</td>
<td>26.1</td>
</tr>
<tr>
<td>75-79</td>
<td>120,154</td>
<td>14.8</td>
</tr>
<tr>
<td>80-84</td>
<td>62,325</td>
<td>7.8</td>
</tr>
<tr>
<td>85+</td>
<td>34,313</td>
<td>4.2</td>
</tr>
<tr>
<td>All</td>
<td>812,471</td>
<td>100.0</td>
</tr>
<tr>
<td><strong>Age (Mean, SD)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>72.6</td>
<td>6.1</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>361,280</td>
<td>44.8</td>
</tr>
<tr>
<td><strong>Comorbidity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>84,325</td>
<td>10.4</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>15,316</td>
<td>1.9</td>
</tr>
<tr>
<td>Ischaemic stroke</td>
<td>16,304</td>
<td>1.9</td>
</tr>
<tr>
<td>Hypertension</td>
<td>519,694</td>
<td>64.0</td>
</tr>
<tr>
<td>Ischaemic heart disease</td>
<td>184,421</td>
<td>20.6</td>
</tr>
<tr>
<td>Cardiomyopathy</td>
<td>11,474</td>
<td>1.4</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>74,949</td>
<td>9.2</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>167,444</td>
<td>20.6</td>
</tr>
<tr>
<td>COPD*</td>
<td>65,566</td>
<td>8.1</td>
</tr>
<tr>
<td>Sleep apnea</td>
<td>18,847</td>
<td>2.3</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>30,284</td>
<td>3.7</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>45,280</td>
<td>5.6</td>
</tr>
<tr>
<td><strong>Hospitalisation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 1 Hospitalisation</td>
<td>204,983</td>
<td>25.2</td>
</tr>
</tbody>
</table>

*COPD: Chronic obstructive pulmonary disease
Table 2: Sex-stratified crude and standardised prevalence of atrial fibrillation in 2004 to 2007

<table>
<thead>
<tr>
<th>Year</th>
<th>Men Crude (%)</th>
<th>Men 95% CI</th>
<th>Men Stand.</th>
<th>Women Crude (%)</th>
<th>Women 95% CI</th>
<th>Women Stand.</th>
<th>All Crude (%)</th>
<th>All 95% CI</th>
<th>All Stand.</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>8.1</td>
<td>(8.0-8.2)</td>
<td>9.3</td>
<td>(9.2-9.4)</td>
<td>5.9</td>
<td>(5.8-6.0)</td>
<td>7.2</td>
<td>(7.1-7.3)</td>
<td>7.1</td>
</tr>
<tr>
<td>2005</td>
<td>8.9</td>
<td>(8.8-9.0)</td>
<td>10.3</td>
<td>(10.2-10.4)</td>
<td>6.4</td>
<td>(6.3-6.5)</td>
<td>8.0</td>
<td>(7.8-8.1)</td>
<td>7.8</td>
</tr>
<tr>
<td>2006</td>
<td>9.3</td>
<td>(9.2-9.4)</td>
<td>10.8</td>
<td>(10.7-10.9)</td>
<td>6.5</td>
<td>(6.4-6.6)</td>
<td>8.2</td>
<td>(8.1-8.4)</td>
<td>8.1</td>
</tr>
<tr>
<td>2007</td>
<td>9.8</td>
<td>(9.7-9.9)</td>
<td>11.4</td>
<td>(11.3-11.5)</td>
<td>6.8</td>
<td>(6.7-6.9)</td>
<td>8.7</td>
<td>(8.6-8.8)</td>
<td>8.5</td>
</tr>
</tbody>
</table>

*Stand.= Standardised (Standardisation was based on the population distribution of Germany of the respective year)*

*Stand.= Standardised (Standardisation was based on the population distribution of Germany of the respective year)
Table 3: Sex-stratified crude and standardised incidence rate of atrial fibrillation per 1,000 person-years in 2007

<table>
<thead>
<tr>
<th>Age groups</th>
<th>Men</th>
<th>Women</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cases*</td>
<td>Rate**</td>
<td>95% CI</td>
</tr>
<tr>
<td></td>
<td>py*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-69</td>
<td>197,042</td>
<td>3,128</td>
<td>15.9 (15.3-16.4)</td>
</tr>
<tr>
<td>70-74</td>
<td>105,412</td>
<td>2,765</td>
<td>26.2 (25.3-27.2)</td>
</tr>
<tr>
<td>75-79</td>
<td>52,526</td>
<td>1,975</td>
<td>37.6 (36.0-39.3)</td>
</tr>
<tr>
<td>80-84</td>
<td>20,468</td>
<td>1,084</td>
<td>53.0 (49.9-56.2)</td>
</tr>
<tr>
<td>85-89</td>
<td>6,041</td>
<td>426</td>
<td>70.5 (64.0-77.5)</td>
</tr>
<tr>
<td>90+</td>
<td>1,716</td>
<td>137</td>
<td>79.9 (67.1-94.4)</td>
</tr>
<tr>
<td>All</td>
<td>383,205</td>
<td>9,515</td>
<td>24.8 (24.3-25.3)</td>
</tr>
<tr>
<td>Stand.****</td>
<td>30.3</td>
<td></td>
<td>(29.6-31.0)</td>
</tr>
</tbody>
</table>

*py = person years

**Newly diagnosed AF patients

***per 1,000 py

****Stand. = Standardised (Standardisation was based on the population distribution of Germany of the respective year)
Table 4: Antithrombotic therapy in patients with newly diagnosed atrial fibrillation by therapy approach

<table>
<thead>
<tr>
<th>Antithrombotic therapy*</th>
<th>Rhythm control</th>
<th>Rate control</th>
<th>Neither</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
<td>95% CI</td>
<td>n</td>
</tr>
<tr>
<td>All</td>
<td>1,475</td>
<td>75.2</td>
<td>(73.2-77.0)</td>
<td>3,690</td>
</tr>
<tr>
<td>Vitamin K antagonists</td>
<td>1,143</td>
<td>58.3</td>
<td>(56.1-60.4)</td>
<td>2,286</td>
</tr>
<tr>
<td>≥ 2 prescriptions</td>
<td>456</td>
<td>23.2</td>
<td>(21.4-25.2)</td>
<td>854</td>
</tr>
<tr>
<td>Antiplatelet drugs</td>
<td>444</td>
<td>22.6</td>
<td>(20.8-24.5)</td>
<td>1,453</td>
</tr>
<tr>
<td>≥ 2 prescriptions</td>
<td>192</td>
<td>9.8</td>
<td>(8.6-11.2)</td>
<td>678</td>
</tr>
<tr>
<td>Low molecular weight heparin</td>
<td>565</td>
<td>28.8</td>
<td>(26.8-30.8)</td>
<td>1,148</td>
</tr>
<tr>
<td>≥ 2 prescriptions</td>
<td>226</td>
<td>11.5</td>
<td>(10.2-13.0)</td>
<td>481</td>
</tr>
<tr>
<td>Unfractionated heparin</td>
<td>13</td>
<td>0.7</td>
<td>(0.4-1.1)</td>
<td>32</td>
</tr>
<tr>
<td>≥ 2 prescriptions</td>
<td>5</td>
<td>0.3</td>
<td>(0.1-0.6)</td>
<td>9</td>
</tr>
<tr>
<td>Other antithrombotic agents</td>
<td>14</td>
<td>0.7</td>
<td>(0.4-1.2)</td>
<td>28</td>
</tr>
<tr>
<td>≥ 2 prescriptions</td>
<td>5</td>
<td>0.3</td>
<td>(0.1-0.6)</td>
<td>10</td>
</tr>
</tbody>
</table>

*Patients could have received more than one drug
Table 5: Adjusted risk for lack of therapy with oral anticoagulants after incident AF diagnosis

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Risk for lack of therapy with oral anticoagulants</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
</tr>
<tr>
<td>65-69</td>
<td>1.0</td>
</tr>
<tr>
<td>70-74</td>
<td>1.0</td>
</tr>
<tr>
<td>75-79</td>
<td>1.0</td>
</tr>
<tr>
<td>80-84</td>
<td>1.6</td>
</tr>
<tr>
<td>85-89</td>
<td>2.2</td>
</tr>
<tr>
<td>≥90</td>
<td>12.4</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>1.0</td>
</tr>
<tr>
<td>Women</td>
<td>1.3</td>
</tr>
<tr>
<td><strong>Therapy approach</strong></td>
<td></td>
</tr>
<tr>
<td>Rhythm control</td>
<td>1.0</td>
</tr>
<tr>
<td>Rate control</td>
<td>2.1</td>
</tr>
<tr>
<td>Neither</td>
<td>5.0</td>
</tr>
<tr>
<td><strong>Comorbidities</strong></td>
<td></td>
</tr>
<tr>
<td>Ischaemic stroke*</td>
<td>0.8</td>
</tr>
<tr>
<td>Myocardial infarction*</td>
<td>1.2</td>
</tr>
<tr>
<td>Valvular heart disease*</td>
<td>0.8</td>
</tr>
<tr>
<td>Diabetes mellitus*</td>
<td>0.9</td>
</tr>
<tr>
<td>Chronic renal failure*</td>
<td>1.3</td>
</tr>
<tr>
<td><strong>CHA²DS²-VASc score</strong></td>
<td></td>
</tr>
<tr>
<td>≥2</td>
<td>1.0</td>
</tr>
<tr>
<td>0-1</td>
<td>1.5</td>
</tr>
</tbody>
</table>

*Reference category = No